Samsung Electronics has decided to support Samsung Biologics with Moderna’s COVID-19 vaccine. Samsung Biologics provides contract development and manufacturing services for a variety of products for the biopharmaceutical industry.
On July 28, Moderna announced a problem with a foreign vaccine plant. This announcement could potentially have an impact on Samsung Biologics, as the company is now preparing to start production of a vaccine. But the preparation process would be useless if undiluted vaccine solutions were not supplied from factories abroad. Industry insiders believe the problem arose at a plant in Switzerland, which is responsible for the production and supply of undiluted vaccines for Samsung Biologics.
Samsung Biologics intends to prepare its manufacturing system so that it can begin production as soon as undiluted vaccine solutions arrive. One of the most important things in the vaccine manufacturing process is keeping the manufacturing areas clean. In the field of clean room technology, Samsung Electronics is the most advanced in the world.
If Samsung Electronics ‘cleanroom technology is added to Samsung Biologics’ manufacturing expertise, Moderna can expect faster technology transfer to Samsung Biologics and improved vaccine production.
Moderna has selected Korea as the only country for contract manufacturing of its vaccines in the world, excluding the United States and Europe. Since vaccination rates in Asia are significantly lower than those in the United States and Europe, repeated supply delays could have negative consequences for Asia as well as Korea.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
